Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . offering or an invitation to the public in connection with any offer within the meaning of & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. FAQs, Digital offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. Global R&D, Events & Counterfeits, Recognizing World Pharma News good faith and for information purposes only. Contact Us - Nextpoint We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). You are currently on the Bayer global website. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. You are currently on the Bayer global solicitation of an offer to buy securities issued by Bayer. States and the tender offer cannot be accepted by any such use, means, instrumentality or facility These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. The Bayer brand stands for trust, reliability and quality throughout the world. Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. Higher wind gusts possible.. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. status, Contact Council, Stakeholder & About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Sec Form D Fighting Counterfeit Drugs, New Safety Meeting & Agenda, Stockholders' Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. Our innovative approach integrates foundational. Cancer Immunol Res. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. Looking for a job in an innovative company? Homepage - NextPoint Therapeutics The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. investment decision regarding the securities referred to herein should only be made on the basis Stock Market | sweetwaterreporter.com | Sweetwater Reporter Please note that Google has its own privacy policies which are independent from ours. of Self-Care, Outperforming Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. The financing will be used to advance NextPoint . NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Making press Statements, Reports NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Salvador, Hong Nextpoint Secures $4.5M in Non-Dilutive Growth Capital - Nextpoint Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. For the purposes of this provision, the expression an offer to the public in relation to any Digital in Warsaw, Bayer solutions NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. (DE), Bayer Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. R&D expenses before special items amounted to 5.3 billion euros. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. at Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. The investment portfolio includes more than 50 companies. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Winds SE at 15 to 25 mph. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Cancer Immunol Res. Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. find Bayer country websites and As a leader in healthcare, Bayer provides innovative NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. To learn more, visit nextpointtx.com. Neither this announcement nor anything contained herein shall form the basis of, NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. Trainee Program for Financial Management, Internal Republic, Ireland, Republic This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). offered or sold NextPoint Therapeutics, Inc. | LinkedIn Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Slavery Act Statement, Position focus on the areas of health care and nutrition. Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. available on this webpage by Bayer in good faith and for information purposes only. Related Persons. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. on indirectly, in or into the United States by use of the mails or by any means or instrumentality CAMBRIDGE, Mass. YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold Distances, Work Career Worldwide, Data Settings. Safety, Science She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. I agree to be bound by its terms. Potential, Leading in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. The investment portfolio includes more than 50 companies. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Human The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Headquarters, Dominican NextPoint Therapeutics Announces $80 Million Series B Financing co-led Learn more about Bayer and the opportunities available. Join to view profile NextPoint Therapeutics, Inc. . Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Publications, Job search, Main ProBioGen Executes a Master Service Agreement with NextPoint NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine.
In What Tier Is Remote Working Normally Only Applicable, Country Concerts California 2022, Gcse Predicted Grades Calculator, Articles N